Oppenheimer has initiated coverage on Guardian Pharmacy Services Inc (GRDN) with an Outperform rating as of October 9, 2025. This marks the firm's first assessment of the company's investment potential. Currently priced at $28.01, Guardian Pharmacy Services operates within the retail industry and provides essential services to long-term care communities.
Headquartered in Atlanta, Georgia, Guardian Pharmacy Services employs approximately 3,400 full-time staff. The company went public on September 26, 2024. It partners with long-term care facilities to deliver medications and a suite of technology-enabled services aimed at enhancing patient care and improving adherence to drug regimens. The company's Guardian Compass platform offers real-time operational insights, while its GuardianShield products enhance clinical services for residents and caregivers alike.
As of November 20, 2025, Guardian Pharmacy Services has a market capitalization of $1.8 billion, with a P/E ratio of 43.49 and an EPS of 0.64. Upcoming earnings are anticipated on August 10, 2026, with an estimated EPS of $0.21 and revenue of $358.2 million. Analyst consensus indicates a Buy rating, with 4 Strong Buy, 5 Buy, and 1 Hold rating among 10 analysts.
Analyst ratings reflect professional opinions grounded in research and financial models. While they can provide valuable insights, these assessments are based on assumptions that may not always materialize. Investors should consider a range of factors, including company fundamentals and market trends, when making decisions.